References
Oliveira KCS, Ramos IB, Silva JMC, et al. Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of cancer. Mol Cancer Res. 2020;18:517–28.
Baumgartner JM, Raymond VM, Lanman RB, et al. Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival. Ann Surg Oncol. 2018;25:2400–8.
Sugimori M, Sugimori K, Tsuchiya H, et al. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Sci. 2020;111:266–78.
Leick KM, Kazarian AG, Rajput M, et al. Peritoneal cell-free tumor DNA as biomarker for peritoneal surface malignancies. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08832-9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
The author declares that there is no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chan, C.H.F. ASO Author Reflections: Potential Values of Peritoneal Cell-Free Tumor DNA Testing. Ann Surg Oncol 27, 5072–5073 (2020). https://doi.org/10.1245/s10434-020-08913-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08913-9